ORLANDO, FL, USA (UroToday.com) - In this study, patient characteristics data on second-line therapies and outcomes were analyzed for patients with metastatic renal cell carcinoma (RCC) who received anti-VEGF therapy at seven centers.
Your session will expire in 8 hours requiring you to log in each day to view content.